Reduced cannabinoid CB 1 receptor binding in alcohol dependence measured with positron emission tomography

Molecular Psychiatry

Volumn 18, Issue 8, 2013, Pages 916-921

  Hirvonen, J ^a   Zanotti Fregonara, P ^a   Umhau, J C ^b   George, D T ^b   Rallis Frutos, D ^a   Lyoo, C H ^a   Li, C T ^a   Hines, C S ^a   Sun, H ^b   Terry, G E ^a   Morse, C ^a   Zoghbi, S S ^a   Pike, V W ^a   Innis, R B ^a   Heilig, M ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

alcohol dependence; cannabinoid CB1 receptor; endocannabinoid; imaging; positron emission tomography

Indexed keywords

BENZODIAZEPINE; CANNABINOID 1 RECEPTOR; OXAZEPAM; RADIOLIGAND; CNR1 PROTEIN, HUMAN;

ADULT; ALCOHOL ABSTINENCE; ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ALCOHOL REHABILITATION PROGRAM; ALCOHOL WITHDRAWAL; ALCOHOLISM; ALLELE; AMYGDALOID NUCLEUS; ANTERIOR CINGULATE; ARTICLE; BODY MASS; CAUDATE NUCLEUS; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRINKING BEHAVIOR; FUNCTIONAL NEUROIMAGING; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; HOSPITAL ADMISSION; HUMAN; INSULA; MALE; MESENCEPHALON; OCCIPITAL CORTEX; PARAHIPPOCAMPAL GYRUS; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PUTAMEN; RECEPTOR BINDING; RECEPTOR DENSITY; RECEPTOR GENE; TEMPORAL CORTEX; THALAMUS; WHITE MATTER; BRAIN; CASE CONTROL STUDY; GENETICS; METABOLISM; SCINTISCANNING;

ADULT; ALCOHOLISM; ALLELES; BRAIN; CASE-CONTROL STUDIES; FUNCTIONAL NEUROIMAGING; HUMANS; MALE; RECEPTOR, CANNABINOID, CB1;

EID: 84881159670     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2012.100     Document Type: Article

References (49)

1. Maccioni P, Colombo G, Carai MA. Blockade of the cannabinoid CB1 receptor and alcohol dependence: Preclinical evidence and preliminary clinical data. CNS Neurol Disord Drug Targets 2010; 9: 55-59
2. Mechoulam R, Parker L. Cannabis and alcohol-A close friendship. Trends Pharmacol Sci 2003; 24: 266-268
3. Basavarajappa BS. The endocannabinoid signaling system: A potential target for next-generation therapeutics for alcoholism. Mini Rev Med Chem 2007; 7: 769-779
4. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR et al. Cannabinoid Receptor Localization in Brain. Proc Natl Acad Sci 1990; 87: 1932-1936
5. Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997; 77: 299-318
6. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202
7. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science 2002; 296: 678-682
8. Colombo G, Serra S, Vacca G, Carai M, Gessa G. Endocannabinoid system and alcohol addiction: Pharmacological studies. Pharmacol Biochem Behav 2005; 81: 369-380
9. Hungund BL, Szakall I, Adam A, Basavarajappa BS, Vadasz C. Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens. J Neurochem 2003; 84: 698-704
10. Wang L, Liu J, Harvey-White J, Zimmer A, Kunos G. Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc Natl Acad Sci 2003; 100: 1393-1398
11. Racz I, Bilkei-Gorzo A, Toth ZE, Michel K, Palkovits M, Zimmer A. A critical role for the cannabinoid CB1 receptors in alcohol dependence and stress-stimulated ethanol drinking. J Neurosci 2003; 23: 2453-2458
12. Rodriguez de Fonseca F, Roberts AJ, Bilbao A, Koob GF, Navarro M. Cannabinoid receptor antagonist SR141716A decreases operant ethanol self administration in rats exposed to ethanol-vapor chambers. Zhongguo Yao Li Xue Bao 1999; 20: 1109-1114
13. Arnone M, Maruani J, Chaperon F, Thiebot MH, Poncelet M, Soubrie P et al. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology 1997; 132: 104-106
14. Colombo G, Agabio R, Fa M, Guano L, Lobina C, Loche A et al. Reduction of voluntary ethanol intake in ethanol-preferring sP rats by the cannabinoid antagonist SR-141716. Alcohol Alcohol 1998; 33: 126-130
15. Basavarajappa BS, Cooper TB, Hungund BL. Chronic ethanol administration downregulates cannabinoid receptors in mouse brain synaptic plasma membrane. Brain Res 1998; 793: 212-218
16. Vinod K, Yalamanchili R, Xie S, Cooper T, Hungund B. Effect of chronic ethanol exposure and its withdrawal on the endocannabinoid system. Neurochem Int 2006; 49: 619-625
17. Mitrirattanakul S, Ló pez-Valdé s HE, Liang J, Matsuka Y, Mackie K, Faull KF et al. Bidirectional alterations of hippocampal cannabinoid 1 receptors and their endogenous ligands in a rat model of alcohol withdrawal and dependence. Alcohol Clin Exp Res 2007; 31: 855-867
18. Vinod KY, Kassir SA, Hungund BL, Cooper TB, Mann JJ, Arango V. Selective alterations of the CB1 receptors and the fatty acid amide hydrolase in the ventral striatum of alcoholics and suicides. J Psychiatric Res 2010; 44: 591-597
19. Zhang PW, Ishiguro H, Ohtsuki T, Hess J, Carillo F, Walther D et al. Human cannabinoid receptor 1: 50 exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol Psychiatry 2004; 9: 916-931
20. Hutchison KE, Haughey H, Niculescu M, Schacht J, Kaiser A, Stitzel J et al. The incentive salience of alcohol: Translating the effects of genetic variant in CNR1. Arch Gen Psychiatry 2008; 65: 841-850
21. Terry GE, Hirvonen J, Liow JS, Zoghbi SS, Gladding R, Tauscher JT et al. Imaging and quantitation of cannabinoid CB1 receptors in human and monkey brains using (18)F-labeled inverse agonist radioligands. J Nucl Med 2010; 51: 112-120
22. Donohue SR, Krushinski JH, Pike VW, Chernet E, Phebus L, Chesterfield AK et al. Synthesis, ex vivo evaluation, and radiolabeling of potent 1,5-diphenylpyrrolidin-2-one cannabinoid subtype-1 receptor ligands as candidates for in vivo imaging. J Med Chem 2008; 51: 5833-5842
23. Diagnostic and Statistical Manual of Mental Disorders 4th edn., text revision. American Psychiatric Association: Washington, DC, 2000
24. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSMIV Axis I Disorders, Clinician Version (SCID-CV). American Psychiatric Press: Washington, DC, 1996
25. Skinner HA, Allen BA. Alcohol dependence syndrome: Measurement and validation. J Abnorm Psychol 1982; 91: 199-209
26. Sobell LC, Sobell MB. Timeline follow-back: A technique for assessing self-reported ethanol consumption, In: Measuring Alcohol Consumption: Psychosocial and Biochemical Methods, Allen, J, Litten, R (eds). 41-72. Humana Press, Totowa, NJ, 1992
27. Flannery BA, Volpicelli JR, Pettinati HM. Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res 1999; 23: 1289-1295
28. Svanborg P. State and Trait Measures in the Affective Disorders. Karolinska Institute, Department of Clinical Neuroscience, Psychiatry Institute: Stockholm, 1999
29. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: The revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 1989; 84: 1353-1357
30. Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, Morse C et al. Reversible and regionally selective downregulation of brain cannabinoid CB(1) receptors in chronic daily cannabis smokers. Mol Psychiatry 2012; 17: 642-649
31. Gandelman MS, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Innis RB. Evaluation of ultrafiltration for the free-fraction determination of single photon emission computed tomography (SPECT) radiotracers: Beta-CIT, IBF, and iomazenil. J Pharm Sci 1994; 83: 1014-1019
32. Zoghbi SS, Shetty HU, Ichise M, Fujita M, Imaizumi M, Liow JS et al. PET imaging of the dopamine transporter with 18F-FECNT: A polar radiometabolite confounds brain radioligand measurements. J Nucl Med 2006; 47: 520-527
33. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002; 15: 273-289
34. Burger C, Mikolajczyk K, Grodzki M, Rudnicki P, Szabatin M, Buck A. Java tools for quantitative post-processing of brain PET data. J Nucl Med 1998; 39: 277p-278p.
35. Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith C, Frackowiak RSJ. Statistical parametric maps in functional imaging: A general linear approach. Hum Brain Mapp 1995; 2: 189-210
36. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 1533-1539
37. Quarantelli M, Berkouk K, Prinster A, Landeau B, Svarer C, Balkay L et al. Integrated software for the analysis of brain PET/SPECT studies with partial-volume-effect correction. J Nucl Med 2004; 45: 192-201
38. Terry G, Liow J, Chernet E, Zoghbi S, Phebus L, Felder C et al. Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB1 receptors in rodents. Neuroimage 2008; 41: 690-698
39. Caille S, Alvarez-Jaimes L, Polis I, Stouffer DG, Parsons LH. Specific Alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-Administration. J Neurosci 2007; 27: 3695-3702
40. Gonzalez S, Fernandez-Ruiz J, Sparpaglione V, Parolaro D, Ramos JA. Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB(1) receptor binding and mRNA levels. Drug Alcohol Depend 2002; 66: 77-84
41. Koob GF, Le Moal M. Addiction and the brain antireward system. Annu Rev Psychol 2008; 59: 29-53
42. Koob GF. A role for brain stress systems in addiction. Neuron 2008; 59: 11-34
43. Hill MN, Patel S, Campolongo P, Tasker JG, Wotjak CT, Bains JS. Functional interactions between stress and the endocannabinoid system: From synaptic signaling to behavioral output. J Neurosci 2010; 30: 14980-14986
44. Hill MN, McEwen BS. Involvement of the endocannabinoid system in the neurobehavioural effects of stress and glucocorticoids. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 791-797
45. Soyka M, Koller G, Schmidt P, Lesch O-M, Leweke M, Fehr C et al. Cannabinoid Receptor 1 Blocker Rimonabant (SR 141716) for Treatment of Alcohol Dependence. J Clin Psychopharmacol 2008; 28: 317-324
46. George DT, Herion DW, Jones CL, Phillips MJ, Hersh J, Hill D et al. Rimonabant (SR141716) has no effect on alcohol self-Administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers. Psychopharmacology 2009; 208: 37-44
47. Cippitelli A, Cannella N, Braconi S, Duranti A, Tontini A, Bilbao A et al. Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse behaviours in the rat. Psychopharmacology 2008; 198: 449-460
48. Umhau JC, Momenan R, Schwandt ML, Singley E, Lifshitz M, Doty L et al. Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: A randomized controlled experimental medicine study. Arch Gen Psychiatry 2010; 67: 1069-1077
49. Rubio M, Villain H, Docagne F, Roussel BD, Ramos JA, Vivien D et al. Pharmacological activation/inhibition of the cannabinoid system affects alcohol withdrawal-induced neuronal hypersensitivity to excitotoxic insults. PloS one 2011; 6: E23690